home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9406d.zip
/
M9460728.TXT
< prev
next >
Wrap
Text File
|
1994-06-25
|
3KB
|
45 lines
Document 0728
DOCN M9460728
TI Survival differences in European patients with AIDS, 1979-89. The AIDS
in Europe Study Group.
DT 9408
AU Lundgren JD; Pedersen C; Clumeck N; Gatell JM; Johnson AM; Ledergerber
B; Vella S; Phillips A; Nielsen JO; University of Copenhagen, Hvidovre
Hospital, Denmark.
SO BMJ. 1994 Apr 23;308(6936):1068-73. Unique Identifier : AIDSLINE
MED/94227645
AB OBJECTIVES--To examine the pattern of survival and factors associated
with the outcome of disease in patients with AIDS. DESIGN--Inception
cohort. Data collected retrospectively from patients' charts.
SETTING--52 clinical centres in 17 European countries. SUBJECTS--6578
adults diagnosed with AIDS from 1 January 1979 to 31 December 1989. MAIN
OUTCOME MEASURES--Survival after the time of diagnosis. RESULTS--The
median survival after diagnosis was 17 months, with an estimated
survival at three years of 16% (95% confidence interval 15% to 17%).
Patients diagnosed in southern Europe had a shorter survival,
particularly immediately after the time of diagnosis, compared with
patients diagnosed in central and northern Europe (survival at one year
(95% confidence interval) 54% (52% to 56%) 66% (64% to 68%), 65% (63% to
66%), respectively. The three year survival, however, was similar for
all regions. The regional differences in survival were less pronounced
for patients diagnosed in 1989 compared with earlier years. Improved
survival in recent years was observed for patients with a variety of
manifestations used to define AIDS but was significant only for patients
diagnosed with Pneumocystis carinii pneumonia. The three year survival,
however, remains unchanged over time. CONCLUSIONS--Survival of AIDS
patients seems to vary within Europe, being shorter in southern than
central and northern Europe. The magnitude of these differences,
however, has declined gradually over time. Short term survival has
improved in recent years, but the long term prognosis has remained
equally poor, reflecting the fact that the underlying infection with HIV
and many of the complicating diseases remains essentially uncontrolled.
DE Acquired Immunodeficiency Syndrome/DRUG THERAPY/IMMUNOLOGY/ *MORTALITY
Adult Cohort Studies Europe/EPIDEMIOLOGY Female Human Leukocyte
Count Male Multivariate Analysis Prognosis Retrospective Studies
Support, Non-U.S. Gov't Survival Analysis Time Factors T4 Lymphocytes
Zidovudine/THERAPEUTIC USE JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).